Various FLT3 inhibitors are currently under development, and midostaurin (PKC412, Novartis) was approved in 2017 as a first-generation inhibitor for FLT3-ITD- and FLT3-TKD-positive AML in the United States [6, 9–11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.